HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3
HAEMONETICS CORP
Financials through Q1 FY2027, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 6, 2026
$118.73+0.45 (+0.38%)
Close on Oct 19, 2026
- Market cap
- $5.43B
- P/E (TTM)
- 57.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
59.0%+13.3 pts over 5 years
Operating margin
11.7%+1.4 pts over 5 years
Net margin
7.3%−1.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -2.0% | +4.5% | +8.9% | +3.9% | |
| Gross profit | +5.2% | +8.6% | +14.6% | +6.9% | |
| Operating income | -29.3% | +0.1% | +11.8% | – | |
| Net income | -42.0% | -5.5% | +4.1% | – | |
| EPS, diluted | -38.1% | -2.9% | +5.8% | – | |
| Free cash flow | +82.8% | +47.2% | +29.4% | +29.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -3.6% | 12.1% | 12.0% | |
| Return on assets | -2.1% | 5.1% | 4.0% | |
| Current ratio | 2.42 | 2.74 | 2.95 | |
| Debt to equity | 0.43 | 0.97 | 1.54 | |
| Net debt to EBITDA | 2.49× | 2.96× | 3.65× | |
| Interest coverage | – | 9.5× | 8.1× | |
| Inventory turnover | 2.8× | 1.6× | 1.6× | |
| Capex to revenue | 8.6% | 4.3% | 2.5% | |
| Diluted shares | 52M | 51M | 47M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Haemonetics generated $1.10B from operations and spent $873.02M on capital expenditure, dividends and share buybacks. 46% of that went back into the business.
Generated
$1.10B
Used
$873.02M
Capital expenditure$398.02M46%Dividends$00%Share buybacks$475.00M54%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin7.3%
×Asset turnover0.55×
×Equity multiplier3.00×
=Return on equity, FY202612.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 7.3% | 0.55× | 3.00× | 12.0% |
| FY2025 | 12.3% | 0.59× | 2.61× | 18.8% |
| FY2024 | 9.0% | 0.63× | 2.32× | 13.2% |
| FY2023 | 9.9% | 0.62× | 2.42× | 14.7% |
| FY2022 | 4.4% | 0.54× | 2.48× | 5.9% |
| FY2021 | 9.1% | 0.56× | 2.34× | 12.1% |
| FY2020 | 7.7% | 0.78× | 2.03× | 12.2% |
| FY2019 | 5.7% | 0.77× | 1.77× | 7.7% |
| FY2018 | 5.0% | 0.73× | 1.66× | 6.1% |
| FY2017 | -3.0% | 0.69× | 1.75× | -3.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
6of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$97.31M
- Cash generatingOperating cash flow above zero$293.22M
- Return on assets improvedROA up on the prior year7.6% → 4.0%
- Earnings backed by cashOperating cash flow above net income$293.22M vs $97.31M
- Less leverageLong-term debt to assets fell37.6% → 50.9%
- Better liquidityCurrent ratio rose1.62 → 2.95
- No dilutionShare count did not rise51M → 47M
- Gross margin improvedGross margin up on the prior year55.04% → 59.04%
- More efficientAsset turnover rose0.62 → 0.54